Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Methodological standard

Draft standard: determination of chromatographic purity by reverse-phase high-performance liquid chromatography

Consultation on the draft of the Institute's first analytical standard, which specifies the performance a chromatographic purity determination must achieve and states, without qualification, that the resulting figure is a relative ultraviolet area and not a…

Document identifier
CEI-CP-004
Series
Public comment period
Version
1.0
Published
30 Jun 2023
Last reviewed
30 Jun 2023
Next review
30 Jun 2024
Identifier
10.71829/cei.cp.4
Certainty
Not rated
Cycle
2023 Q2
Window
28 Apr 2023 – 28 May 2023
Status
Closed
Submissions
5

§1Consultation and window

§1.1Window

Opened
28 April 2023
Closed
28 May 2023
Duration
30 days
Status
Closed — the disposition is published
Document under consultation
Standard CEI-MS-01
Submissions received
5

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Are the system suitability criteria appropriate across the range of peptide lengths and hydrophobicities in scope?
  2. Is the requirement to state the integration start time workable for laboratories operating validated legacy methods?
  3. Does the standard state clearly enough what a purity figure determined under it does not establish, in particular in relation to counter-ion content and to species that do not elute?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The standard was amended before ratification, principally to state performance rather than to prescribe a single gradient, and to carry a worked example showing the same chromatogram integrated two ways.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.